

ATC codes: **L01DB01**

Indication	Other specified malignant neoplasms of breast <span style="float: right;">ICD11 code: <b>2D1Y</b></span>
INN	Doxorubicin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)
EML status history	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Doxorubicin</a> 
DrugBank	<a href="#">Doxorubicin</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

[Expert Committee report](#) 

